87 related articles for article (PubMed ID: 30453728)
41. Epithelial ovarian cancer: Evolution of management in the era of precision medicine.
Lheureux S; Braunstein M; Oza AM
CA Cancer J Clin; 2019 Jul; 69(4):280-304. PubMed ID: 31099893
[TBL] [Abstract][Full Text] [Related]
42. Can we predict who lives long with ovarian cancer?
Bookman MA
Cancer; 2019 Dec; 125 Suppl 24():4578-4581. PubMed ID: 31967684
[TBL] [Abstract][Full Text] [Related]
43. Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer.
Kim SI; Song M; Hwangbo S; Lee S; Cho U; Kim JH; Lee M; Kim HS; Chung HH; Suh DS; Park T; Song YS
Cancer Res Treat; 2019 Jul; 51(3):1144-1155. PubMed ID: 30453728
[TBL] [Abstract][Full Text] [Related]
44. Development and validation of nomograms for epithelial ovarian cancer: a SEER population-based, real-world study.
Wang R; Xie G; Shang L; Qi C; Yang L; Huang L; Li D; Yang W
Future Oncol; 2021 Mar; 17(8):893-906. PubMed ID: 33533669
[No Abstract] [Full Text] [Related]
45. Impact of antibiotic treatment during platinum chemotherapy on survival and recurrence in women with advanced epithelial ovarian cancer.
Chambers LM; Kuznicki M; Yao M; Chichura A; Gruner M; Reizes O; Debernardo R; Rose PG; Michener C; Vargas R
Gynecol Oncol; 2020 Dec; 159(3):699-705. PubMed ID: 32950250
[TBL] [Abstract][Full Text] [Related]
46. Preoperative albumin-to-fibrinogen ratio predicts chemotherapy resistance and prognosis in patients with advanced epithelial ovarian cancer.
Yu W; Ye Z; Fang X; Jiang X; Jiang Y
J Ovarian Res; 2019 Sep; 12(1):88. PubMed ID: 31533857
[TBL] [Abstract][Full Text] [Related]
47. [The relationship of preoperativelymphocyte-monocyte ratio and the clinicopathological characteristics and prognosis of patients with epithelial ovarian cancer].
Yang HM; Lou G
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):676-680. PubMed ID: 28926896
[No Abstract] [Full Text] [Related]
48. Predicting 6- and 12-Month Risk of Mortality in Patients With Platinum-Resistant Advanced-Stage Ovarian Cancer: Prognostic Model to Guide Palliative Care Referrals.
Foote J; Lopez-Acevedo M; Samsa G; Lee PS; Kamal AH; Alvarez Secord A; Havrilesky LJ
Int J Gynecol Cancer; 2018 Feb; 28(2):302-307. PubMed ID: 29360690
[TBL] [Abstract][Full Text] [Related]
49. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard I; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P;
Lancet Oncol; 2017 Sep; 18(9):1274-1284. PubMed ID: 28754483
[TBL] [Abstract][Full Text] [Related]
50. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL; Brady MF; Herzog TJ; Sabbatini P; Armstrong DK; Walker JL; Kim BG; Fujiwara K; Tewari KS; O'Malley DM; Davidson SA; Rubin SC; DiSilvestro P; Basen-Engquist K; Huang H; Chan JK; Spirtos NM; Ashfaq R; Mannel RS
Lancet Oncol; 2017 Jun; 18(6):779-791. PubMed ID: 28438473
[TBL] [Abstract][Full Text] [Related]
51. Cancer Statistics, 2017.
Siegel RL; Miller KD; Jemal A
CA Cancer J Clin; 2017 Jan; 67(1):7-30. PubMed ID: 28055103
[TBL] [Abstract][Full Text] [Related]
52. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
[TBL] [Abstract][Full Text] [Related]
53. The Global Burden of Cancer 2013.
; Fitzmaurice C; Dicker D; Pain A; Hamavid H; Moradi-Lakeh M; MacIntyre MF; Allen C; Hansen G; Woodbrook R; Wolfe C; Hamadeh RR; Moore A; Werdecker A; Gessner BD; Te Ao B; McMahon B; Karimkhani C; Yu C; Cooke GS; Schwebel DC; Carpenter DO; Pereira DM; Nash D; Kazi DS; De Leo D; Plass D; Ukwaja KN; Thurston GD; Yun Jin K; Simard EP; Mills E; Park EK; Catalá-López F; deVeber G; Gotay C; Khan G; Hosgood HD; Santos IS; Leasher JL; Singh J; Leigh J; Jonas JB; Sanabria J; Beardsley J; Jacobsen KH; Takahashi K; Franklin RC; Ronfani L; Montico M; Naldi L; Tonelli M; Geleijnse J; Petzold M; Shrime MG; Younis M; Yonemoto N; Breitborde N; Yip P; Pourmalek F; Lotufo PA; Esteghamati A; Hankey GJ; Ali R; Lunevicius R; Malekzadeh R; Dellavalle R; Weintraub R; Lucas R; Hay R; Rojas-Rueda D; Westerman R; Sepanlou SG; Nolte S; Patten S; Weichenthal S; Abera SF; Fereshtehnejad SM; Shiue I; Driscoll T; Vasankari T; Alsharif U; Rahimi-Movaghar V; Vlassov VV; Marcenes WS; Mekonnen W; Melaku YA; Yano Y; Artaman A; Campos I; MacLachlan J; Mueller U; Kim D; Trillini M; Eshrati B; Williams HC; Shibuya K; Dandona R; Murthy K; Cowie B; Amare AT; Antonio CA; Castañeda-Orjuela C; van Gool CH; Violante F; Oh IH; Deribe K; Soreide K; Knibbs L; Kereselidze M; Green M; Cardenas R; Roy N; Tillmann T; Li Y; Krueger H; Monasta L; Dey S; Sheikhbahaei S; Hafezi-Nejad N; Kumar GA; Sreeramareddy CT; Dandona L; Wang H; Vollset SE; Mokdad A; Salomon JA; Lozano R; Vos T; Forouzanfar M; Lopez A; Murray C; Naghavi M
JAMA Oncol; 2015 Jul; 1(4):505-27. PubMed ID: 26181261
[TBL] [Abstract][Full Text] [Related]
54. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial.
Pujade-Lauraine E; Hilpert F; Weber B; Reuss A; Poveda A; Kristensen G; Sorio R; Vergote I; Witteveen P; Bamias A; Pereira D; Wimberger P; Oaknin A; Mirza MR; Follana P; Bollag D; Ray-Coquard I
J Clin Oncol; 2014 May; 32(13):1302-8. PubMed ID: 24637997
[TBL] [Abstract][Full Text] [Related]
55. A prognostic nomogram to predict overall survival in women with recurrent ovarian cancer treated with bevacizumab and chemotherapy.
Previs RA; Bevis KS; Huh W; Tillmanns T; Perry L; Moore K; Chapman J; McClung C; Kiet T; Java J; Chan J; Secord AA
Gynecol Oncol; 2014 Mar; 132(3):531-6. PubMed ID: 24472410
[TBL] [Abstract][Full Text] [Related]
56. Incidence of cervical, endometrial, and ovarian cancer in Korea, 1999-2010.
Lim MC; Moon EK; Shin A; Jung KW; Won YJ; Seo SS; Kang S; Kim JW; Kim JY; Park SY
J Gynecol Oncol; 2013 Oct; 24(4):298-302. PubMed ID: 24167664
[TBL] [Abstract][Full Text] [Related]
57. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer.
Lee CK; Simes RJ; Brown C; Gebski V; Pfisterer J; Swart AM; Berton-Rigaud D; Plante M; Skeie-Jensen T; Vergote I; Schauer C; Pisano C; Parma G; Baumann K; Ledermann JA; Pujade-Lauraine E; Bentley J; Kristensen G; Belau A; Nankivell M; Canzler U; Lord SJ; Kurzeder C; Friedlander M
Ann Oncol; 2013 Apr; 24(4):937-43. PubMed ID: 23104722
[TBL] [Abstract][Full Text] [Related]
58. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C; Blank SV; Goff BA; Judson PL; Teneriello MG; Husain A; Sovak MA; Yi J; Nycum LR
J Clin Oncol; 2012 Jun; 30(17):2039-45. PubMed ID: 22529265
[TBL] [Abstract][Full Text] [Related]
59. Nomogram for predicting 5-year disease-specific mortality after primary surgery for epithelial ovarian cancer.
Barlin JN; Yu C; Hill EK; Zivanovic O; Kolev V; Levine DA; Sonoda Y; Abu-Rustum NR; Huh J; Barakat RR; Kattan MW; Chi DS
Gynecol Oncol; 2012 Apr; 125(1):25-30. PubMed ID: 22155261
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
